Patents by Inventor Gaozhong Zhu

Gaozhong Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for CNS delivery of iduronate-2-sulfatase
    Patent number: 8545837
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.
    Type: Grant
    Filed: June 25, 2011
    Date of Patent: October 1, 2013
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Gaozhong Zhu, Kris Lowe, Zahra Shahrokh, James Christian, Richard Fahmer, Jing Pan, Teresa Leah Wright, Pericles Calias
  • METHODS AND COMPOSITIONS FOR CNS DELIVERY OF HEPARAN N-SULFATASE
    Publication number: 20120014936
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising a heparan N-sulfatase (HNS) protein, salt, and a polysorbate surfactant for the treatment of Sanfilippo Syndrome Type A.
    Type: Application
    Filed: June 25, 2011
    Publication date: January 19, 2012
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Farah Natoli, Gaozhong Zhu, Jennifer Terew, Yuan Jiang, Jamie Tsung, Zahra Shahrokh, Brian Vernaglia, Jing Pan, Richard Pfeifer, Pericles Calias
  • METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE
    Publication number: 20110318323
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.
    Type: Application
    Filed: June 25, 2011
    Publication date: December 29, 2011
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Gaozhong Zhu, Kris Lowe, Zahra Shahrokh, James Christian, Rick Richard Fahmer, Jing Pan, Teresa Leah Wright, Pericles Calias
  • METHODS AND COMPOSITIONS FOR CNS DELIVERY OF B-GALACTOCEREBROSIDASE
    Publication number: 20110318324
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an B-Galactocerebrosidase protein, salt, and a polysorbate surfactant for the treatment of GLD Disease.
    Type: Application
    Filed: June 25, 2011
    Publication date: December 29, 2011
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Ken Manning, Gaozhong Zhu, Paul Campolieto, Zahra Shahrokh, Pericles Calias, Thomas McCauley
  • STABILIZED COMPOSITIONS OF PROTEINS HAVING A FREE THIOL MOIETY
    Publication number: 20110091414
    Abstract: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.
    Type: Application
    Filed: October 12, 2010
    Publication date: April 21, 2011
    Inventors: Gaozhong Zhu, Vinh T. Nguyen, Kris Lowe, Zahra Shahrokh
  • Stabilized compositions of proteins having a free thiol moiety
    Patent number: 7833766
    Abstract: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: November 16, 2010
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Gaozhong Zhu, Vinh T. Nguyen, Kris Lowe, Zahra Shahrokh
  • METHODS FOR STABILIZING BIOLOGICALLY ACTIVE AGENTS ENCAPSULATED IN BIODEGRADABLE CONTROLLED-RELEASE POLYMERS
    Publication number: 20080182909
    Abstract: Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method comprises preparing PLGA delivery systems whose microclimate, i.e. the pores where the active agent resides, uniformly or homogenously maintain a pH of between 3 and 9, preferably between 4 and 8, more preferably between 5 and 7.5 during biodegradation.
    Type: Application
    Filed: September 27, 2007
    Publication date: July 31, 2008
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Steven P. Schwendeman, Gaozhong Zhu, Hanne Bentz, Jeffrey A. Hubbell, Wenlei Jiang, Anna Shenderova, Jichao Kang
  • STABILIZED COMPOSITIONS OF PROTEINS HAVING A FREE THIOL MOIETY
    Publication number: 20070197439
    Abstract: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.
    Type: Application
    Filed: February 6, 2007
    Publication date: August 23, 2007
    Inventors: Gaozhong Zhu, Vinh Nguyen, Kris Lowe, Zahra Shahrokh
  • Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
    Publication number: 20040105878
    Abstract: Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method comprises preparing a PLGA delivery systems whose microclimate, i.e. the pores where the active agent resides, uniformly or homogenously maintain a pH of between 3 and 9, preferably between 4 and 8, more preferably between 5 and 7.5 during biodegradation.
    Type: Application
    Filed: November 3, 2003
    Publication date: June 3, 2004
    Inventors: Steven P. Schwendeman, Gaozhong Zhu, Hanne Bentz, Jeffrey A. Hubbell, Wenlei Jiang, Anna Shenderova, Jichao Kang
  • Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
    Patent number: 6743446
    Abstract: Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method comprises preparing a PLGA delivery systems whose microclimate, i.e. the pores where the active agent resides, uniformly or homogenously maintain a pH of between 3 and 9, preferably between 4 and 8, more preferably between 5 and 7.5 during biodegradation.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: June 1, 2004
    Assignee: The Ohio State University Research Foundation
    Inventors: Steven P. Schwendeman, Gaozhong Zhu, Hanne Bentz, Jeffrey A. Hubbell, Wenlei Jiang, Anna Shenderova, Jichao Kang
  • Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
    Publication number: 20020009493
    Abstract: Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method comprises preparing a PLGA delivery systems whose microclimate, i.e. the pores where the active agent resides, uniformly or homogenously maintain a pH of between 3 and 9, preferably between 4 and 8, more preferably between 5 and 7.5 during biodegradation.
    Type: Application
    Filed: December 15, 2000
    Publication date: January 24, 2002
    Inventors: Steven P. Schwendeman, Gaozhong Zhu, Hanne Bentz, Jeffrey A. Hubbell, Wenlei Jiang, Anna Shenderova, Jichao Kang